Criteria of Cheson et al for Disease Progression or Relapse After Hematologic Improvement Following Therapy for Myelodysplastic Syndrome (International Working Group to Standardize Response Criteria)

 

Patient selection: hematologic improvement after cytotoxic therapy for MDS

 

Criteria for progression or relapse - one or more of the following:

(1) >= 50% decrease in absolute neutrophil count from maximum response

(2) >= 50% decrease in platelet count from maximum response

(3) reduction in hemoglobin concentration by >= 2.0 g/dL

(4) red blood cell transfusion dependence

(5) platelet transfusion dependence

 

Exclusion:

(1) Gastrointestinal bleeding or other disorder that can explain the findings.

(2) Chemotherapy effect.